Inhibrx Biosciences Inc [INBX] stock prices are up 1.15% to $28.2 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The INBX shares have gain 12.80% over the last week, with a monthly amount glided 28.65%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
The stock price of Inhibrx Biosciences Inc [INBX] has been fluctuating between $10.81 and $28.16 over the past year. Inhibrx Biosciences Inc [NASDAQ: INBX] shares were valued at $28.2 at the most recent close of the market.
Analyzing the INBX fundamentals
The Inhibrx Biosciences Inc [NASDAQ:INBX] reported sales of 1.40M for trailing twelve months, representing a surge of 1200.00%. Gross Profit Margin for this corporation currently stands at -0.99% with Operating Profit Margin at -119.3%, Pretax Profit Margin comes in at -116.92%, and Net Profit Margin reading is -116.92%. To continue investigating profitability, this company’s Return on Assets is posted at -0.77, Equity is -1.38 and Total Capital is -0.96. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.11.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 27.77 points at the first support level, and at 27.33 for the second support level. However, for the 1st resistance point, the stock is sitting at 28.46, and for the 2nd resistance point, it is at 28.72.
Ratios To Look Out For
It’s worth pointing out that Inhibrx Biosciences Inc [NASDAQ:INBX]’s Current Ratio is 4.98. Further, the Quick Ratio stands at 4.98, while the Cash Ratio is 4.79. Considering the valuation of this stock, the price to sales ratio is 291.78, the price to book ratio is 5.95.
Transactions by insiders
Recent insider trading involved Kayyem Jon Faiz, Director, that happened on Nov 19 ’24 when 69686.0 shares were purchased. Director, Kayyem Jon Faiz completed a deal on Nov 20 ’24 to buy 37500.0 shares. Meanwhile, Chief Executive Officer Lappe Mark bought 26963.0 shares on Sep 12 ’24.
